Cancer-fighting Peninsula company postpones $92 million IPO

The company has planned for the IPO proceeds to fund clinical trials in experimental cancer and inflammation drugs.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.